Abstract:Abstract Head and neck squamous cell carcinoma (HNSCC) is the sixth most common malignancy worldwide. The vast majority of the human HNSCCs contain p53 mutations, some of which acquire oncogenic gain-of-function (GOF) activities. Previous mouse models in which either the p53R172H GOF mutation or deletion of the p53 gene were co-activated with oncogenic K-ras showed that p53R172H can predispose to oral tumor initiation, accelerate tumor growth and promote progression to SCC. However, the impact of p53 gain- and loss-of-function (LOF) mutations in metastasis could not be assessed because of the low rates of progression to SCC in that model. To overcome this limitation, we used the tobacco-surrogate 4NQO to induce oral lesions that may progress to advance carcinomas following stepwise changes that resemble the gradual accumulation of histological and molecular abnormalities observed during human oral cancer progression. To examine the role of p53 mutations during SCC malignant progression we applied 4NQO to mice in which the p53R172H mutation or homozygous deletion of p53 were activated in oral epithelial cells. We observed that oral tumors appeared faster in the presence of p53 mutations than in mice with wtp53. No significant difference was observed between the p53R172H mutation and p53 deletion. However, survival was shorter in mice expressing p53R172H than in mice with loss of p53. Notably, regional and distant metastasis were only observed in mice with oral tumors expressing p53R172H. Therefore, these mice are excellent tools for pre-clinical studies designed to target early stages of tumor development or latest stages of progression and metastasis. As immunotherapy is becoming adopted as part of the standard treatment for head and neck cancer patients, we conducted a detailed characterization of the immune infiltrates of the lesions that developed in these mice in order to assess their immunogenicity. We observed a progressive increase in T-cell infiltration from normal oral mucosa to oral premalignant lesions (OPL) to SCC, in the presence or absence of p53 mutations. Similarly, the expression of immune checkpoint proteins, including PD1, PDL1 and CTLA4 increased during oral tumor progression, regardless of the p53 status. Interestingly, we observed a sharp increase in the presence of immune infiltrates expressing the co-stimulatory OX40 in SCCs relative to premalignant lesions, with different extent depending on the nature of the p53 mutation. The significance of these observations is currently being analyzed. In summary, p53R172H promotes metastasis in oral tumors induced by 4NQO. In addition, T-cell infiltration and activation of immune checkpoints during oral tumor progression suggest that this is an excellent model to test immunotherapy-based strategies. Furthermore, our findings suggest that OX40-based therapies may be tailored to patients according to their p53 status. Citation Format: Jin Wang, Yuanyuan Zhang, Bingbing Wang, Adel K. El-Naggar, Jeffrey N. Myers, Carlos Caulin. Mutant p53 promotes progression and metastasis of mouse oral tumors induced by 4NQO, associated with specific immune infiltrates [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 1845. doi:10.1158/1538-7445.AM2017-1845

Syngeneic animal models of tobacco-associated oral cancer reveal the activity of in situ anti-CTLA-4

Novel Syngeneic Animal Model of Tobacco-Associated Oral Cancer Reveals the Activity of in Situ Anti-Ctla-4

An HNSCC syngeneic mouse model for tumor immunology research and preclinical evaluation

Mouse Models for Head and Neck Squamous Cell Carcinoma

Mouse Models for Human Head and Neck Squamous Cell Carcinomas

Polymorphonuclear myeloid-derived suppressor cells and phosphatidylinositol-3 kinase gamma are critical to tobacco-mimicking oral carcinogenesis in mice

A novel orthotopic mouse model of head and neck cancer and lymph node metastasis

Abstract. The lack of reliable animal models to assess the safety and efficacy of drugs and to explore the underlying molecular mechanisms is one of the most severe impedi- ments in head and neck squamous cell carcinoma (HNSCC)

Mouse Models for Immune Checkpoint Blockade Therapeutic Research in Oral Cancer

Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments

Towards system genetics analysis of head and neck squamous cell carcinoma using the mouse model, cellular platform, and clinical human data

Comparative Analysis of Tumor-Infiltrating Lymphocytes in a Syngeneic Mouse Model of Oral Cancer

Lymphatic-preserving treatment sequencing with immune checkpoint inhibition unleashes cDC1-dependent antitumor immunity in HNSCC

Inhibition of SRC Family Kinases Facilitates Anti-Ctla4 Immunotherapy in Head and Neck Squamous Cell Carcinoma

Development of an Orthotopic HPV16-Dependent Base of Tongue Tumor Model in MHC-Humanized Mice

Abstract 1509: Identification of Immunotherapy Resistance Mechanisms Within Tumor Microenvironment in a Mouse Model of Oral Squamous Cell Carcinoma

A Novel Immunocompetent Preclinical Mouse Model to Uncover Oncogenic Initiators of Head and Neck Cancer

Abstract 1845: Mutant P53 Promotes Progression and Metastasis of Mouse Oral Tumors Induced by 4NQO, Associated with Specific Immune Infiltrates

Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV+ oral cancer

Immunocompromised and Immunocompetent Mouse Models for Head and Neck Squamous Cell Carcinoma

Targeting of Interleukin-13 Receptor Α2 for Treatment of Head and Neck Squamous Cell Carcinoma Induced by Conditional Deletion of TGF-β and PTEN Signaling